Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Age-adjusted High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation or Conventional Chemotherapy With R-MP as First-line Treatment in Elderly Primary CNS Lymphoma Patients - a Randomized Phase III Trial

NCT06830421 is registered in ClinicalTrials.gov with University Hospital Freiburg as lead sponsor.

NCT NCT06830421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06830421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Age-adjusted High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation or Conventional Chemotherapy With R-MP as First-line Treatment in Elderly Primary CNS Lymphoma Patients - a Randomized Phase III Trial
Lead sponsor
University Hospital Freiburg
Phase
Phase 3
Overall status
Recruiting
Start date
August 9, 2023
Completion date
August 31, 2031
Enrollment
340 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma